AstraZeneca jumps 4% after COPD drug wins Phase 3 trials. Tozorakimab success seen as rare win in tough COPD drug race.

AstraZeneca shares jump sharply amid strong premarket trading; Institutional activity reflects growing interest across healthcare sector; Biopharma pipeline continues ...

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company. Already ...

Drugs giant AstraZeneca has notched up a 40% surge in annual profits and forecast further growth in earnings over the year ahead as it continues to put faith in strong demand for its cancer treatments ...

Total Revenue up 11% to $43,236m, driven by growth in all Therapy Areas, including 16% growth in Oncology and 13% growth in R&I Growth in Total Revenue across all major geographic regions Core ...

Corebridge Financial Inc. lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 37,867 shares of the company’s ...

U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country -- ...